Form 4: Syros Pharmaceuticals Director Acquires Shares and Options

Director Andrew M. Oh acquired 4,000 shares of common stock and options to purchase 6,000 shares of Syros Pharmaceuticals on June 5, 2024.

Summary

• On June 5, 2024, Andrew M. Oh, a director of Syros Pharmaceuticals, acquired 4,000 shares of common stock at $0.00 per share.
• Following this transaction, Mr. Oh directly owns 16,000 shares of Syros Pharmaceuticals.
• Mr. Oh also acquired options to purchase 6,000 shares of common stock at an exercise price of $5.30.
• These options vest in installments, starting six months after the grant date, with full vesting one year from the grant date, contingent upon continued service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options by a director could be interpreted as a positive sign, but it's not a strong indicator on its own.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.

Key Dates

Keywords

Syros Pharmaceuticals, Director, Share Acquisition, Stock Options, Form 4, Beneficial Ownership, Securities